Objective: After prostate biopsy, serious and life-threatening infections of resistant strains can develop and therefore fluoroquinolones for prophylaxis is widely used. This study aimed to examine infections in patients undergoing transrectal prostate biopsy with quinolone prophylaxis and to review the articles reported in this respect.
INTRODUCTION
Prostate cancer is the one of most commonly diagnosed cancer in the United States and is the second cause of cancer-specific deaths among men [1] . Widely used for the diagnosis of prostate cancer, transrectal ultrasound (TRUS)-guided prostate biopsy is usually safe and easy method. However, biopsyrelated pain, hematuria, hematospermia, rectal bleeding, urinary retention, dysuria, urinary tract infection (UTI), acute bacterial prostatitis, epididymoorchitis and rarely sepsis have been reported [2, 3] . Sepsis following biopsy is less likely to occur (0.1 to 7%), however, it has a severe course [4, 5] .
Prophylactic antibiotic is used to reduce infectious complications after prostate biopsy. Fluoroquinolones are commonly used antibiotics, in that they could be orally used, diffuse well into the prostatic tissue, have long term urinary bactericidal activity in TRUS-guided biopsy of the prostate [3] . However, the increased resistance to quinolone complicates the choice of the drug used in prophylaxis. This study aimed to evaluate infections occurring following prostate biopsy with the use of quinolone prophylaxis and to keep in mind that resistant strains may be causative agents in patients presenting with infection and to evaluate the effectiveness of prophylaxis in the light of literature.
MATERIALS AND METHODS
A total of 1760 TRUS-guided prostate biopsies were carried out between January 2005 and December 2010 in Haydarpasa Numune Training and Research Hospital in Istanbul. It was performed from 12 different locations also an 8-dose ciprofloxacin and cleansing enema were applied before the biopsy procedure. All cases underwent urinalysis prior to biopsy. Fourteen patients were followed up due to infection after prostate biopsy and the clinical characteristics of patients, underlying diseases, and laboratory data were retrospectively evaluated.
Empirical antibiotic therapy was performed in patients with infection after prostate biopsy, taking urine culture, and blood cultures in our department. Microorganisms growing in blood culture were identified using conventional methods; antibiotic susceptibilities were determined according to Clinical and Laboratory and Standards Institute (CLSI) criteria [6] .
Statistical analyses were performed with the use of SPSS version 16.0 (SPSS Inc., Chicago, USA). Descriptive statistics of the variables were given as mean, standard deviation, and median (minimummaximum).
RESULTS
Fourteen cases (the mean age 62.8 ± 7.7 years; range 49 to 76) developed infection after TRUS-guided prostate biopsy. The length of hospital stay was 17.6 ± 6.6 days and the median time from biopsy to presentation to our department was 3 days (range, 1 to 8 days) all cases had fluoroquinolone prophylaxis. One patient was diagnosed with acute bacterial prostatitis (7.1%), 3 (21.4%) with UTI, and 10 (71.4%) with septic manifestations. Of 10 patients developing sepsis, 7 patients had (70%) severe sepsis.
Thirteen cases (92.8%) had high fever ( Table 1 ). Median serum prostate specific antigen was 23 ng/ml E. coli was cultured in the blood of 7 patients (50%) and in the urine of 12 patients (85.7%); both the blood and urine culture of 5 patients (35.7%) grew E. coli. Six patients (42.8%) had positive extended spectrumlactamases (ESBL) and 13 patients (92.8%) had quinolone resistance. Figure 1 shows the antibiotic susceptibilities of quinolone-resistant E. coli strains. Ceftriaxone was administered to four cases, while 10 cases (71.4 %) presenting with sepsis were administered carbapenem. No cases had mortal course. 
DISCUSSION
Prostate biopsy is performed after giving of prophylactic antibiotics to reduce infection. There are a large number of antibiotics or antibiotic regimens recommended for prophylaxis [7] [8] [9] [10] [11] . High-dose shortterm fluoroquinolone prophylaxis, and disinfection of the rectum with 10% povidone-iodine are recommended in Japanese guideline [12] . American Urological Association recommends that prophylactic fluoroquinolone or the 1 st the 2 nd and the 3 rd generation cephalosporins for prostate biopsy, and specifies that aminoglycoside plus metronidazole or clindamycin could be used as an alternative therapy [13] . Fluoroquinolones are used for prophylaxis in patients undergoing prostate biopsy in our hospital. Despite quinolone prophylaxis, 14 patients developed infection after biopsy in this study. Seven of these patients were admitted to our department with clinically severe sepsis. Quinolone resistance in 92.8% of E. coli strains raises questions about the effectiveness of prophylaxis.
E. coli is the most frequently isolated pathogen in patients with infection after prostate biopsy [14, 15] . Quinolone resistance and ESBL rates continue to rise in E. coli. According to the CDC, quinolone resistance to E. coli increased from 0.8% in 1990 to 3.7% 1999 [16] . Ciprofloxacin sensitivity of E. coli isolated from urinary tract infections was 43.2% between 2009 and 2010 based upon the results of the SMART study [17] . In a study performed for E. coli strains of urinary origin in our hospital, while ESBL rate was 5% in 2004, it was determined to be 12.2% in 2010; resistance to ciprofloxacin in ESBL positive strains was found to be 72.4% in 2010 [18] . We detected a high quinolone resistance in E. coli strains. Increased resistance requires monitoring of antimicrobial resistance in order to determine the use of the drug in prophylaxis by centers.
In a study carried out with E. coli strains isolated from urinary tract infections by Azap et al. It was reported that use of beta-lactam antibiotics 3 months before biopsy and three times or more frequent occurrence of UTIs and prostatic disease a year before biopsy were accompanied by ESBL positivity [19] . As previous use of antibiotics is a risk factor for development of bacterial colonization with resistant strains or infection, it requires being cautious especially in the prophylaxis of patients at risk. It is known that examination of rectal swab samples for resistant 
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The literature reports that quinolone resistance has been established to be 14% to 100% in patients developing infection following prostate biopsy [8, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] ( Table 2) . Carignan et al. reported that 5798 prostate biopsies were performed and that a significant increase in infection rates were detected between 2010 and 2011 as compared with those between 2002 and 2009 [31] . Increased fluoroquinolone resistance was implicated to be the cause of rise in infection rates in this study.
Extended-spectrum beta-lactamases are the enzymes that affect monobactams, cephalosporins, but not carbapenems. Even if the minimal inhibitory concentration (MIC) value of cephalosporins selected for treatment is precise in severe infections caused by ESBL-producing organisms, treatment failure is likely to occur. High cross-resistance has been observed in the ESBL-producing organisms, trimethoprim-sulfamethoxazole, amoxicillin-clavulanate and fluoroquinolones. Therefore, carbapenems remain the first choice in severe infections [32] . In our study, 10 patients presented to our clinic with sepsis. For these cases, carbapenem was preferred as empirical therapy. Our cases recovered from sepsis with carbapenem therapy, resulting in cure.
Our study has some limitations. In our hospital, 1760 prostate biopsies were performed between 2005 and 2010.However, the patients were not followed-up after biopsy. This study was conducted retrospectively and only the patients who were admitted to our clinic were examined. The infection rates of prostate biopsies could not be given, because patients undergoing prostate biopsies may also have applied to other clinics. It could not be found out from clinical recordings whether patients had received antibiotics before biopsy, whereas the previous antibiotic use is a risk factor for resistant bacterial infections [19] .
CONCLUSION
As a result, increased antimicrobial resistance in E. coli strains forces us to find new choices for prophylaxis. This study suggested that fluoroquinolone resistant E. coli should be considered as an important causative agent in infections after transrectal prostate biopsy. In centers with high resistance to quinolone, prophylactic use of broad-spectrum antibiotics poses a risk for infections of resistant strains. Therefore screening rectal swab samples for resistant microorganisms before biopsy, choice of antibiotic prophylaxis based on antimicrobial sensitivity test would be an appropriate approach for the prevention of lifethreatening infections.
